Back to top
more

United Therapeutics Corporation (UTHR)

(Delayed Data from NSDQ)

$194.30 USD

194.30
293,090

+4.42 (2.33%)

Updated May 11, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (206 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for United Therapeutics Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 1,835 1,486 1,416 927 1,051
Receivables 157 151 176 297 215
Notes Receivable 0 0 0 0 0
Inventories 87 93 101 108 100
Other Current Assets 88 134 75 116 60
Total Current Assets 2,167 1,865 1,768 1,448 1,425
Net Property & Equipment 732 739 700 546 489
Investments & Advances 1,150 768 443 503 2
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 239 230 96 113 178
Intangibles 158 158 171 46 34
Deposits & Other Assets 170 155 224 224 197
Total Assets 4,615 3,913 3,401 2,879 2,326
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 187 148 166 171 104
Current Portion Long-Term Debt 0 250 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 136 65 111 274 228
Total Current Liabilities 323 463 277 445 333
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 800 600 250 250 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 97 70 86 83 142
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,220 1,133 612 778 474
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 2,149 2,048 1,940 1,854 1,814
Retained Earnings 3,839 3,325 3,435 2,846 2,434
Other Equity -14 -14 -8 -20 -17
Treasury Stock 2,579 2,579 2,579 2,579 2,380
Total Shareholder's Equity 3,395 2,780 2,789 2,102 1,851
Total Liabilities & Shareholder's Equity 4,615 3,913 3,401 2,879 2,326
Total Common Equity 3,395 2,780 2,789 2,102 1,851
Shares Outstanding 44.40 43.80 43.50 43.20 42.40
Book Value Per Share 76.47 63.48 64.11 48.65 43.66

Fiscal Year End for United Therapeutics Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 1,731 1,835 1,581 1,561 1,545
Receivables 141 157 152 172 150
Notes Receivable 0 0 0 0 0
Inventories 92 87 88 90 92
Other Current Assets 50 88 48 72 60
Total Current Assets 2,014 2,167 1,868 1,894 1,846
Net Property & Equipment 714 732 736 744 739
Investments & Advances 1,434 1,150 1,228 1,009 868
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 264 239 256 246 246
Intangibles 45 158 158 158 158
Deposits & Other Assets 171 170 165 167 168
Total Assets 4,641 4,615 4,411 4,219 4,026
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 165 187 177 153 130
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 137 136 82 102 77
Total Current Liabilities 302 323 259 255 207
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 800 800 800 800 800
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 93 69 71 70
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,196 1,220 1,128 1,126 1,077
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 2,173 2,149 2,126 2,105 2,068
Retained Earnings 3,868 3,839 3,740 3,569 3,462
Other Equity -17 -14 -5 -2 -4
Treasury Stock 2,579 2,579 2,579 2,579 2,579
Total Shareholder's Equity 3,445 3,395 3,283 3,094 2,949
Total Liabilities & Shareholder's Equity 4,641 4,615 4,411 4,219 4,026
Total Common Equity 3,445 3,395 3,283 3,094 2,949
Shares Outstanding 44.80 44.40 44.40 44.40 44.00
Book Value Per Share 76.91 76.47 73.94 69.68 67.01